Skip to main content
Essential ThrombocythemiaDrugPhase 3

What this study is

This study is being conducted to evaluate INCA033989 versus best available therapy in participants with essential thrombocythemia and a CALR mutation previously treated with cytoreductive therapy.

What's being tested

  • INCA033989

    Intervention · DRUG

    Administered intravenous (IV) in accordance with the protocol-defined requirements.

  • Best Available Treatment

    Intervention · DRUG

    Best Available Therapy (BAT) will be selected by the investigator.

Study details

Official title
A Phase 3, Randomized, Open-Label Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia and a CALR Mutation Previously Treated With Cytoreductive Therapy (EXCALIBUR-ET2)
Sponsor
Incyte Corporation
Conditions
Essential Thrombocythemia
Enrolling
426 people
Starts
2026-09-08
Est. completion
2030-11-01
Design
Open-label, randomized, parallel groups, Phase 3
Record
View on ClinicalTrials.gov ↗